SG11202111972YA - Solid forms of a glyt1 inhibitor - Google Patents
Solid forms of a glyt1 inhibitorInfo
- Publication number
- SG11202111972YA SG11202111972YA SG11202111972YA SG11202111972YA SG11202111972YA SG 11202111972Y A SG11202111972Y A SG 11202111972YA SG 11202111972Y A SG11202111972Y A SG 11202111972YA SG 11202111972Y A SG11202111972Y A SG 11202111972YA SG 11202111972Y A SG11202111972Y A SG 11202111972YA
- Authority
- SG
- Singapore
- Prior art keywords
- solid forms
- glyt1 inhibitor
- glyt1
- inhibitor
- solid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962841401P | 2019-05-01 | 2019-05-01 | |
| PCT/US2020/030580 WO2020223419A1 (en) | 2019-05-01 | 2020-04-30 | Solid forms of a glyt1 inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111972YA true SG11202111972YA (en) | 2021-11-29 |
Family
ID=70740812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111972YA SG11202111972YA (en) | 2019-05-01 | 2020-04-30 | Solid forms of a glyt1 inhibitor |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11447474B2 (en) |
| EP (1) | EP3962911A1 (en) |
| JP (1) | JP2022530630A (en) |
| KR (1) | KR20220004174A (en) |
| CN (1) | CN113784966A (en) |
| AR (1) | AR118839A1 (en) |
| AU (1) | AU2020266566A1 (en) |
| BR (1) | BR112021020883A2 (en) |
| CA (1) | CA3138288A1 (en) |
| CL (1) | CL2021002837A1 (en) |
| CO (1) | CO2021014260A2 (en) |
| CR (1) | CR20210545A (en) |
| DO (1) | DOP2021000224A (en) |
| EA (1) | EA202192925A1 (en) |
| EC (1) | ECSP21082195A (en) |
| IL (1) | IL287630A (en) |
| JO (1) | JOP20210295A1 (en) |
| MA (1) | MA55801A (en) |
| MX (1) | MX2021013341A (en) |
| PE (1) | PE20212263A1 (en) |
| SG (1) | SG11202111972YA (en) |
| TW (1) | TW202106680A (en) |
| WO (1) | WO2020223419A1 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7930336B2 (en) | 2006-12-05 | 2011-04-19 | Altera Corporation | Large multiplier for programmable logic device |
| WO2021142329A1 (en) | 2020-01-09 | 2021-07-15 | Disc Medicine, Inc. | Methods of treating erythropoietic protoporphyria, x-linked protoporphyria, or congenital erythropoietic porphyria with glycine transport inhibitors |
| JP2023537963A (en) * | 2020-08-13 | 2023-09-06 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Treatment for cognitive impairment associated with schizophrenia |
| WO2022078927A1 (en) | 2020-10-13 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Process of reworking |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL65843A (en) * | 1977-08-11 | 1986-12-31 | American Cyanamid Co | Pharmaceutical compositions for the treatment of depression containing 3-aza-bicyclo(3.1.0)hexane derivatives and certain novel compounds of this type |
| WO2005037216A2 (en) * | 2003-10-14 | 2005-04-28 | Pfizer Products Inc. | Bicyclic [3.1.0] derivatives as glycine transporter inhibitors |
| AU2009322420A1 (en) * | 2008-12-04 | 2011-06-23 | Sanofi | Novel polymorphic forms of an azabicyclo-trifluoromethyl benzamide derivative |
| WO2010078348A1 (en) * | 2008-12-29 | 2010-07-08 | Vanderbilt University | 3.1.0 bicyclic glyt1 inhibitors and methods of making and using same |
| US9012489B2 (en) * | 2011-08-03 | 2015-04-21 | Boehringer Ingelheim International Gmbh | Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament |
| RU2768473C2 (en) * | 2017-04-27 | 2022-03-24 | Такеда Фармасьютикал Компани Лимитед | Heterocyclic compound |
-
2020
- 2020-04-30 JO JOP/2021/0295A patent/JOP20210295A1/en unknown
- 2020-04-30 DO DO2021000224A patent/DOP2021000224A/es unknown
- 2020-04-30 CA CA3138288A patent/CA3138288A1/en active Pending
- 2020-04-30 CR CR20210545A patent/CR20210545A/en unknown
- 2020-04-30 BR BR112021020883A patent/BR112021020883A2/en unknown
- 2020-04-30 US US16/862,608 patent/US11447474B2/en active Active
- 2020-04-30 EA EA202192925A patent/EA202192925A1/en unknown
- 2020-04-30 KR KR1020217039503A patent/KR20220004174A/en unknown
- 2020-04-30 TW TW109114685A patent/TW202106680A/en unknown
- 2020-04-30 PE PE2021001800A patent/PE20212263A1/en unknown
- 2020-04-30 WO PCT/US2020/030580 patent/WO2020223419A1/en active Application Filing
- 2020-04-30 JP JP2021563717A patent/JP2022530630A/en active Pending
- 2020-04-30 CN CN202080032902.7A patent/CN113784966A/en active Pending
- 2020-04-30 MX MX2021013341A patent/MX2021013341A/en unknown
- 2020-04-30 AU AU2020266566A patent/AU2020266566A1/en active Pending
- 2020-04-30 EP EP20726654.5A patent/EP3962911A1/en active Pending
- 2020-04-30 SG SG11202111972YA patent/SG11202111972YA/en unknown
- 2020-04-30 AR ARP200101242A patent/AR118839A1/en unknown
- 2020-04-30 MA MA055801A patent/MA55801A/en unknown
-
2021
- 2021-10-26 CO CONC2021/0014260A patent/CO2021014260A2/en unknown
- 2021-10-27 IL IL287630A patent/IL287630A/en unknown
- 2021-10-28 CL CL2021002837A patent/CL2021002837A1/en unknown
- 2021-11-17 EC ECSENADI202182195A patent/ECSP21082195A/en unknown
-
2022
- 2022-06-27 US US17/849,935 patent/US20220332710A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CO2021014260A2 (en) | 2021-10-29 |
| PE20212263A1 (en) | 2021-11-29 |
| DOP2021000224A (en) | 2021-12-15 |
| IL287630A (en) | 2021-12-01 |
| CN113784966A (en) | 2021-12-10 |
| US11447474B2 (en) | 2022-09-20 |
| ECSP21082195A (en) | 2021-12-30 |
| WO2020223419A1 (en) | 2020-11-05 |
| MA55801A (en) | 2022-03-09 |
| BR112021020883A2 (en) | 2022-04-19 |
| EA202192925A1 (en) | 2022-03-23 |
| TW202106680A (en) | 2021-02-16 |
| KR20220004174A (en) | 2022-01-11 |
| JOP20210295A1 (en) | 2023-01-30 |
| US20200347041A1 (en) | 2020-11-05 |
| AU2020266566A1 (en) | 2021-11-11 |
| CL2021002837A1 (en) | 2022-07-29 |
| JP2022530630A (en) | 2022-06-30 |
| US20220332710A1 (en) | 2022-10-20 |
| CA3138288A1 (en) | 2020-11-05 |
| MX2021013341A (en) | 2021-11-17 |
| EP3962911A1 (en) | 2022-03-09 |
| CR20210545A (en) | 2021-12-23 |
| AR118839A1 (en) | 2021-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4076418A4 (en) | Sos1 inhibitors | |
| IL290341A (en) | Mta-cooperative prmt5 inhibitors | |
| IL287630A (en) | Solid forms of a glyt1 inhibitor | |
| EP4069212A4 (en) | Inhibitors of hif-2alpha | |
| IL289929A (en) | Crystalline forms of a cd73 inhibitor | |
| IL283608A (en) | 15-pgdh inhibitor | |
| IL290087A (en) | Inhibitor compounds | |
| GB201914860D0 (en) | Inhibitor compounds | |
| GB202004960D0 (en) | Inhibitor compounds | |
| GB202008201D0 (en) | Inhibitor compounds | |
| ZA202109573B (en) | Prmt5 inhibitors | |
| IL292772A (en) | Corrosion inhibitor | |
| IL285427A (en) | Crystalline forms of a jak2 inhibitor | |
| IL279953A (en) | Crystalline forms of a lta4h inhibitor | |
| SG11202107225SA (en) | Crystalline form of a cdk inhibitor | |
| GB201905328D0 (en) | Inhibitor compounds | |
| IL291368A (en) | Inhibitor of metadherin expression | |
| IL292847A (en) | Crystalline forms of a magl inhibitor | |
| IL284222A (en) | Crystalline forms of a par4 inhibitor | |
| GB201905318D0 (en) | Inhibitor compounds | |
| GB201908044D0 (en) | Dopamine-B-Hydroxylase inhibitors | |
| GB202117224D0 (en) | Inhibitor compounds | |
| GB201905476D0 (en) | MAPA4K4 Inhibitors | |
| GB202112240D0 (en) | Inhibitor compounds | |
| GB202110373D0 (en) | Inhibitor compounds |